APA (7th ed.) Citation

Bartlett, N. L., Yasenchak, C. A., Ashraf, K. K., Harwin, W. N., Sims, R. B., & Nowakowski, G. S. (2021). Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress). Journal of clinical oncology, 39(15_suppl), TPS7571. https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS7571

Chicago Style (17th ed.) Citation

Bartlett, Nancy L., Christopher A. Yasenchak, Khaleel K. Ashraf, William N. Harwin, Robert Brownell Sims, and Grzegorz S. Nowakowski. "Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Trials in Progress)." Journal of Clinical Oncology 39, no. 15_suppl (2021): TPS7571. https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS7571.

MLA (9th ed.) Citation

Bartlett, Nancy L., et al. "Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Trials in Progress)." Journal of Clinical Oncology, vol. 39, no. 15_suppl, 2021, p. TPS7571, https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS7571.